{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:00:58Z","timestamp":1788379258230,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2018R1A2B6006178"],"award-info":[{"award-number":["2018R1A2B6006178"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2023R1A2C1007324"],"award-info":[{"award-number":["NRF-2023R1A2C1007324"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vaccine.2024.05.016","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T06:22:47Z","timestamp":1716013367000},"page":"4046-4055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9934-4422","authenticated-orcid":false,"given":"Sol","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ki","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.05.016_b0005","series-title":"Plotkin's Vaccines","first-page":"1268","article-title":"Zoster vaccines","author":"Levin","year":"2018"},{"key":"10.1016\/j.vaccine.2024.05.016_b0010","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1080\/21645515.2019.1603985","article-title":"Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003\u20132015","volume":"15","author":"Choi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.05.016_b0015","doi-asserted-by":"crossref","first-page":"2085468","DOI":"10.1080\/21645515.2022.2085468","article-title":"Estimation of single-dose varicella vaccine effectiveness in South Korea using mathematical modeling","volume":"18","author":"Suh","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.05.016_b0020","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/CVI.00645-13","article-title":"Varicella and varicella vaccination in South Korea","volume":"21","author":"Oh","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2024.05.016_b0025","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/j.vaccine.2019.07.086","article-title":"The changing epidemiology of herpes zoster over a decade in South Korea, 2006\u20132015","volume":"37","author":"Choi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.016_b0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2013.11.018","article-title":"Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical-epidemiological study","volume":"20","author":"Song","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.016_b0035","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2024.05.016_b0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.016_b0045","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.05.016_b0050","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.05.016_b0055","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2024.05.016_b0060","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s13555-022-00744-8","article-title":"Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults","volume":"12","author":"Teng","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.vaccine.2024.05.016_b0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.12811\/kshsm.2018.12.2.063","article-title":"Factors affecting herpes zoster vaccination in adults","volume":"12","author":"Jeong","year":"2018","journal-title":"Korean J Health Serv Manage"},{"key":"10.1016\/j.vaccine.2024.05.016_b0070","unstructured":"Choi WS. Cost-effectiveness analysis of introducing the zoster vaccine into national immunization program in the Repbulic of Korea. Osong, Republic of Korea: Korea Disease Control and Prevention Agency; 2019."},{"key":"10.1016\/j.vaccine.2024.05.016_b0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12916-018-1094-7","article-title":"The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study","volume":"16","author":"Melegaro","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2024.05.016_b0080","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.vaccine.2021.03.056","article-title":"The impact of two-dose varicella vaccination on varicella and herpes zoster incidence in South Korea using a mathematical model with changing population demographics","volume":"39","author":"Suh","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.016_b0085","unstructured":"Population projections for Korea [2017-2067]. Daejeon, Republic of Korea. Korean Statistical information Service; 2017."},{"key":"10.1016\/j.vaccine.2024.05.016_b0090","series-title":"The Population Division of the Department of Economic and Social Affairs","author":"World Population Prospects","year":"2020"},{"key":"10.1016\/j.vaccine.2024.05.016_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jinf.2010.04.001","article-title":"Seroprevalence rate after one dose of varicella vaccine in infants","volume":"61","author":"Kim","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2024.05.016_b0100","first-page":"3549","article-title":"National childhood vaccination coverage among children aged 1\u20133 and 6 years in Korea, 2019","volume":"13","author":"Lee","year":"2020","journal-title":"Public Health Weekly Report"},{"key":"10.1016\/j.vaccine.2024.05.016_b0105","first-page":"36","article-title":"Waning effectiveness of one-dose universal varicella vaccination in Korea, 2011\u20132018: a propensity score matched national population cohort","author":"Hong","year":"2021","journal-title":"J Korea Med Sci"},{"key":"10.1016\/j.vaccine.2024.05.016_b0110","doi-asserted-by":"crossref","first-page":"e20153741","DOI":"10.1542\/peds.2015-3741","article-title":"Global varicella vaccine effectiveness: a meta-analysis","volume":"137","author":"Marin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.05.016_b0115","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1080\/21645515.2021.2002085","article-title":"Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany","volume":"17","author":"Curran","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.05.016_b0120","unstructured":"Lee SG. Immunization rates of vaccines not supported by the nation (PPSV\/PCV, HepB, HZV) and strategy for HBV high risk adults. Osong, Republic of Korea: Korea Disease Control and Prevention Agency; 2020."},{"key":"10.1016\/j.vaccine.2024.05.016_b0125","doi-asserted-by":"crossref","first-page":"e2014008","DOI":"10.4178\/epih\/e2014008","article-title":"A guide for the utilization of health insurance review and assessment service national patient samples","volume":"36","author":"Kim","year":"2014","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.vaccine.2024.05.016_b0130","unstructured":"Disease Subclassification Statistics of the National Health Insurance Sharing Service (NHISS) . National Health Insurance Service of Korea; 2015."},{"key":"10.1016\/j.vaccine.2024.05.016_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3346\/jkms.2016.31.1.13","article-title":"Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX) in Korean Adults","volume":"31","author":"Choi","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2024.05.016_b0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40258-022-00721-4","article-title":"Korean guidelines for pharmacoeconomic evaluations: updates in the third version","volume":"20","author":"Bae","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.vaccine.2024.05.016_b0145","unstructured":"NHIS. Korea Health Insurance Patient Medical Expense Survey (2019). Gangwon-do, Republic of Korea: National Health Insurance Service; 2019."},{"key":"10.1016\/j.vaccine.2024.05.016_b0150","unstructured":"Non-reimbursable medical treatment cost information. Gangwon-do, Republic of Korea Health Insurance Review and Assessment Service; 2021."},{"key":"10.1016\/j.vaccine.2024.05.016_b0155","article-title":"Korean demand for GSK\u2019s Shingrix weaker than expected: dermatologists","author":"Lee","year":"2023","journal-title":"Korea Biomedical Review"},{"key":"10.1016\/j.vaccine.2024.05.016_b0160","series-title":"Shingrix price outline\u2026 Hospital supply price expected to be 160,000\u2013180,000 won","author":"Hwang","year":"2022"},{"key":"10.1016\/j.vaccine.2024.05.016_b0165","unstructured":"Regulations on the outsourcing of national immunization program vaccination Osong, Republic of Korea: Korea Disease Control and Prevention Agency; 2021."},{"key":"10.1016\/j.vaccine.2024.05.016_b0170","article-title":"Cost-effectiveness analysis of introducing the zoster vaccine into National Immunization Program (NIP) of the Republic of Korea","volume":"12","author":"Kim","year":"2019","journal-title":"Public Health Weekly Report"},{"key":"10.1016\/j.vaccine.2024.05.016_b0175","unstructured":"Consumer price index (2021). Korean Statistical Information Service (KOSIS). Daejon, Republic of Korea. Statistics Korea; 2022."},{"key":"10.1016\/j.vaccine.2024.05.016_b0180","unstructured":"Yearly average currency exchange rates. Internal Revenue Service; 2023."},{"key":"10.1016\/j.vaccine.2024.05.016_b0185","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.016_b0190","series-title":"WHO guide for standardization of economic evaluations of immunization programmes","year":"2019"},{"key":"10.1016\/j.vaccine.2024.05.016_b0195","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/0272989X211045070","article-title":"Generating, presenting, and interpreting cost-effectiveness results in the context of uncertainty: a tutorial for deeper knowledge and better practice","volume":"42","author":"Bilcke","year":"2022","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2024.05.016_b0200","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2024.05.016_b0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2024.05.016_b0210","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1086\/522135","article-title":"An economic analysis of the universal varicella vaccination program in the United States","volume":"197","author":"Zhou","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.016_b0215","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1016\/j.vaccine.2020.05.065","article-title":"Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea","volume":"38","author":"Choi","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.016_b0220","first-page":"673","article-title":"Methods for the economic evaluation of health care interventions for priority setting in the health system: an update From WHO CHOICE","volume":"10","author":"Bertram","year":"2021","journal-title":"Int J Health Policy Manag"},{"key":"10.1016\/j.vaccine.2024.05.016_b0225","doi-asserted-by":"crossref","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","article-title":"Understanding the global measurement of willingness to pay in health","volume":"8","author":"McDougall","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.vaccine.2024.05.016_b0230","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.vaccine.2019.05.006","article-title":"Cost-effectiveness of recombinant zoster vaccine (RZV) and varicella vaccine live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan","volume":"37","author":"Hoshi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.016_b0235","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2024.05.016_b0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12916-018-1213-5","article-title":"Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines","volume":"16","author":"de Boer","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2024.05.016_b0245","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2468-2667(17)30234-7","article-title":"Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study","volume":"3","author":"Amirthalingam","year":"2018","journal-title":"Lancet Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24005620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24005620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T10:22:58Z","timestamp":1728642178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24005620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":49,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0264410X24005620"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}